Payment overview · 2025
General Payments
$33.46
2 reported records · 2 companies
Healthcare provider profile · identity verified
Jonathan Winner, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CELINA, OH · NPI 1962639732
Verified facts
What the public records show
CMS Open Payments records show Jonathan Winner, D.O. received $33.46 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 52.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.66 | 52.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.80 | 47.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.46 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
72 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 632 | 183 |
| Lisinopril | Lisinopril | 415 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 91 |
| Losartan Potassium | Losartan Potassium | 269 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 70 |
| Omeprazole | Omeprazole | 239 | 70 |
| Gabapentin | Gabapentin | 210 | 55 |
| Metformin Hcl Er | Metformin Hcl | 201 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 60 |
| Metformin Hcl | Metformin Hcl | 189 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 48 |
| Allopurinol | Allopurinol | 163 | 48 |
| Sertraline Hcl | Sertraline Hcl | 160 | 49 |
| Potassium Chloride | Potassium Chloride | 159 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 36 |
| Simvastatin | Simvastatin | 146 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 45 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 129 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 42 |
| Meloxicam | Meloxicam | 124 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 40 |
| Glimepiride | Glimepiride | 118 | 37 |
| Lorazepam | Lorazepam | 117 | 38 |
| Furosemide | Furosemide | 113 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 28 |
| Alprazolam | Alprazolam | 98 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 32 |
| Tramadol Hcl | Tramadol Hcl | 90 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 20 |
| Warfarin Sodium | Warfarin Sodium | 74 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 72 | 72 |
| Montelukast Sodium | Montelukast Sodium | 72 | 16 |
| Alendronate Sodium | Alendronate Sodium | 67 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 18 |
| Famotidine | Famotidine | 64 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 15 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 54 | 54 |
| Prednisone | Prednisone | 54 | 34 |
| Synthroid | Levothyroxine Sodium | 54 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Atenolol | Atenolol | 50 | 16 |
| Farxiga | Dapagliflozin Propanediol | 50 | 13 |
| Buspirone Hcl | Buspirone Hcl | 47 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Eliquis | Apixaban | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 12 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 24 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Carvedilol | Carvedilol | 37 | 13 |
| Spironolactone | Spironolactone | 37 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Klor-Con M20 | Potassium Chloride | 35 | 12 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Jardiance | Empagliflozin | 33 | 15 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Brilinta | Ticagrelor | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.46 · 2 records | Amgen Inc. | NURTEC ODT, OTEZLA, REPATHA, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error